Seqirus
Clinical trials sponsored by Seqirus, explained in plain language.
A global influenza vaccine company, a subsidiary of CSL.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New adjuvanted flu vaccine aims to boost protection in older adults
⭐️ VACCINE ⭐️ CompletedThis phase 2b trial tests several versions of an experimental flu vaccine that includes an adjuvant (MF59) to strengthen the immune response. The vaccine is made from cells, not eggs, and targets four flu strains. Around 1,000 adults aged 50 and older receive a single shot and ar…
Phase: PHASE2 • Sponsor: Seqirus • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 02, 2026 00:00 UTC
-
New bird flu booster shot shows promise in early trial
⭐️ VACCINE ⭐️ CompletedThis study tested a booster vaccine for H5N6 bird flu in about 260 adults. Some had previously received an H5N1 bird flu vaccine, while others had not. The goal was to see if the booster was safe and triggered a strong immune response. Participants received one or two doses of th…
Phase: PHASE2 • Sponsor: Seqirus • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:33 UTC
-
New flu vaccine shows promise for seniors in massive trial
Prevention CompletedThis large study tested whether an enhanced flu vaccine (Fluad) works better than standard flu shots in adults aged 65 and older. Over 38,000 participants received either Fluad or a regular vaccine. The goal was to see if Fluad prevents confirmed flu cases more effectively. Resul…
Phase: PHASE3 • Sponsor: Seqirus • Aim: Prevention
Last updated Jun 27, 2026 14:03 UTC